Thermo Fisher delivered a robust Q1 with 6% revenue growth to $11.01 billion, driven by strength in biotech and pharma markets, while maintaining disciplined margins and expanding innovative offerings.
- Revenue increased 6% to $11.01 billion; adjusted EPS up 6% to $5.44, supported by a 21.8% operating margin.
- Pharma and biotech markets grew mid-single-digit, led by bioproduction, clinical research, and safety channels.
- Launches included advanced cryo-EM and mass spectrometry solutions, reinforcing industry leadership and customer value.
- Strategic collaborations with NVIDIA and SHL Medical enhance AI-driven workflows and manufacturing capabilities.
- End markets are expected to remain resilient amid macroeconomic uncertainties and ongoing innovation efforts.
Community Discussion